Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A04058 | Pages: 169 | Charts: 32 | Tables: 89 |
The global idiopathic pulmonary fibrosis market size was valued at $3,126.08 million in 2020, and is projected to reach $6,169.37 million by 2030, registering a CAGR of 7.0% from 2021 to 2030. Idiopathic pulmonary fibrosis is a chronic lung disease or a condition in which the tissues in lungs become thick and stiff over time. As a result of thickening of lung tissues, brain, and other organs are unable receive optimum oxygen. This condition causes scar tissue (fibrosis) to build up in the lungs, which makes the lungs unable to transport oxygen into the bloodstream effectively. The disease usually affects people between the ages of 50 and 70. Idiopathic pulmonary fibrosis belongs to a group of conditions called interstitial lung diseases (also known as ILD), which describes lung diseases that involve inflammation or scarring in the lung.
[COVIDIMPACTSTATEMENT]
Idiopathic pulmonary fibrosis is expected to exhibit significant market growth during the forecast period, owing to growth in demand for ideal drugs for treatment of idiopathic pulmonary fibrosis, and favorable reimbursement policies provided by manufacturers & insurance providers in some countries. The key factors driving the market growth include rise in prevalence of fibrotic disease, increase in geriatric population, and technological advancements in screening & diagnosis of cancer further drive the idiopathic pulmonary fibrosis market growth. In addition, surge in demand for cost-effective drugs and introduction of advanced treatment options propel the market growth. However, unavailability of the proper treatment options of the disease restricts the market growth.
Get more information on this report : Request Sample Pages
The idiopathic pulmonary fibrosis market is segmented on the basis of type of drug, distribution channel, and region. According to type of drug, the market is bifurcated into pirfenidone and nintedanib. On the basis of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and online providers. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA).
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted among humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement. Furthermore, the virus has high potential of lethality in geriatric population. On March 11, 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, only a few vaccines that received emergency approvals for COVID-19 prevention. Thus, social distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns.
The overall impact of COVID-19 remains negative on the idiopathic pulmonary fibrosis market, owing to decline in number of idiopathic pulmonary fibrosis patient visits in hospitals & clinics for idiopathic pulmonary fibrosis therapy (IPF), as these patients are more vulnerable to COVID-19 infection which lead to decline in demand for idiopathic pulmonary fibrosis products. Furthermore, most markets are experiencing a decline, especially in the idiopathic pulmonary fibrosis market, owing to the outbreak of COVID-19.
By drug type, the idiopathic pulmonary fibrosis market is divided into nintedanib and pirfenidone. The pirfenidone segment was the major revenue contributor in 2020, and is anticipated to continue this trend during the forecast period, owing to increase in adoption of pirfenidone drug such as Esbriet and Pirespa globally. On the other side, the demand for nintedanib is projected to exhibit the fastest market growth during the forecast period, owing to rise in use of Ofev and surge in R&D studies for nintedanib.
[DRUGTYPEGRAPH]
Get more information on this report : Request Sample Pages
By distribution channel, the idiopathic pulmonary fibrosis market is classified into hospital pharmacies, retail pharmacies, and online providers. The retail pharmacies segment presently dominates the market, and is expected to remain dominant during the forecast period. This segment is expected to exhibit a prominent growth rate, owing to the rapid increase of idiopathic pulmonary fibrosis rate in geriatric population, technological advancements, and lifestyle change across the world.
[DISTRIBUTIONCHANNELGRAPH]
Get more information on this report : Request Sample Pages
By region, the idiopathic pulmonary fibrosis market is analyzed across North America, Asia-Pacific, Europe, and LAMEA. North America dominated the market in 2020, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. The research activities for idiopathic pulmonary fibrosis are soaring in North America due to significant infrastructure for developmental research, availability of substantial research funds, and rise in government initiatives toward idiopathic pulmonary fibrosis are anticipated to drive the market growth.
[REGIONGRAPH]
Get more information on this report : Request Sample Pages
This report provides comprehensive competitive analysis and profiles of prominent idiopathic pulmonary fibrosis market players such as key players operating in the AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim, F. Hoffmann-La Roche, FibroGen, Inc., Mission Therapeutics., GNI Group Ltd, Galapagos NV, Biogen, Bristol-Myers Squibb Company., and Shiongi Co Ltd
Key Benefits For Stakeholders
Key Market Segments
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.1.1.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Top player positioning, 2020
3.4.Porter’s five forces analysis
3.4.1.Bargaining power of suppliers
3.4.2.Bargaining power of buyers
3.4.3.Threat of new entrants
3.4.4.Threat of substitutes
3.4.5.Intensity of competitive rivalry
3.5.MARKET DYNAMICS
3.5.1.Drivers
3.5.1.1.Increase in incidences of cancer across the globe
3.5.1.2.Surge in global geriatric population
3.5.1.3.Increase in cigarette smoking
3.5.2.Restraint
3.5.2.1.Lack of awareness & Proper treatment.
3.5.3.Opportunities
3.5.3.1.Increase in number of pipeline drugs
3.5.3.2.Growth opportunities in emerging markets
3.5.4.Impact analyses
3.6.COVID-19 impact analysis on market
3.7.Pipeline analyses
CHAPTER 4:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Pirfenidone
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country
4.3.Nintedanib
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country
CHAPTER 5:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast, by distribution channel
5.2.Hospital- pharmacies
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Retail pharmacy
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Online Pharmacy
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
CHAPTER 6:IDIOPATHIC PULMONARY FIBROSIS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America market size and forecast, by country
6.2.3.North America market size and forecast, by drug type
6.2.4.North America market size and forecast, by distribution channel
6.2.4.1.U.S.
6.2.4.2.U.S. market size and forecast, by drug type
6.2.4.3.U.S. market size and forecast, by distribution channel
6.2.4.4.Canada
6.2.4.5.Canada market size and forecast, by drug type
6.2.4.6.Canada market size and forecast, by distribution channel
6.2.4.7.Mexico
6.2.4.8.Mexico market size and forecast, by drug type
6.2.4.9.Mexico market size and forecast, by distribution channel
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe market size and forecast, by country
6.3.3.Europe market size and forecast, by drug type
6.3.4.Europe market size and forecast, by distribution channel
6.3.4.1.Germany.
6.3.4.2.Germany market size and forecast, by drug type
6.3.4.3.Germany market size and forecast, by distribution channel
6.3.4.4.France
6.3.4.5.France market size and forecast, by drug type
6.3.4.6.France market size and forecast, by distribution channel
6.3.4.7.UK
6.3.4.8.UK market size and forecast, by drug type
6.3.4.9.UK market size and forecast, by distribution channel
6.3.4.10.Italy
6.3.4.11.Italy market size and forecast, by drug type
6.3.4.12.Italy market size and forecast, by distribution channel
6.3.4.13.Spain
6.3.4.14.Spain market size and forecast, by drug type
6.3.4.15.Spain market size and forecast, by distribution channel
6.3.4.16.Rest of Europe
6.3.4.17.Rest of Europe market size and forecast, by drug type
6.3.4.18.Rest of Europe market size and forecast, by distribution channel
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific market size and forecast, by country
6.4.3.Asia-Pacific market size and forecast, by drug type
6.4.4.Asia-Pacific market size and forecast, by distribution channel
6.4.4.1.Japan
6.4.4.2.Japan market size and forecast, by drug type
6.4.4.3.Japan market size and forecast, by distribution channel
6.4.4.4.China
6.4.4.5.China market size and forecast, by drug type
6.4.4.6.China market size and forecast, by distribution channel
6.4.4.7.India
6.4.4.8.India market size and forecast, by drug type
6.4.4.9.India market size and forecast, by distribution channel
6.4.4.10.Australia
6.4.4.11.Australia market size and forecast, by drug type
6.4.4.12.Australia market size and forecast, by distribution channel
6.4.4.13.South Korea
6.4.4.14.South Korea market size and forecast, by drug type
6.4.4.15.South Korea market size and forecast, by distribution channel
6.4.4.16.Rest of Asia-Pacific
6.4.4.17.Rest of Asia-Pacific market size and forecast, by drug type
6.4.4.18.Rest of Asia-Pacific market size and forecast, by distribution channel
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA market size and forecast, by country
6.5.3.LAMEA market size and forecast, by drug type
6.5.4.LAMEA market size and forecast, by application
6.5.4.1.Brazil
6.5.4.2.Brazil market size and forecast, by drug type
6.5.4.3.Brazil market size and forecast, by distribution channel
6.5.4.4.Saudi Arabia
6.5.4.5.Saudi Arabia market size and forecast, by drug type
6.5.4.6.Saudi Arabia market size and forecast, by distribution channel
6.5.4.7.South Africa
6.5.4.8.South Africa market size and forecast, by drug type
6.5.4.9.South Africa market size and forecast, by distribution channel
6.5.4.10.Rest of LAMEA
6.5.4.11.Rest of LAMEA market size and forecast, by drug type
6.5.4.12.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 7:COMPANY PROFILES
7.1.AstraZeneca Plc.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product Portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.BOEHRINGER INGELHEIM INTERNATIONAL GMBH
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.Bristol-Myers Squibb Company
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.Biogen,Inc
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.FibroGen, Inc
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.F. Hoffmann-La Roche AG
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.GNI Group Ltd.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.Galapagos NV.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.Mission Therapeutics
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.10.Shionogi & Co Ltd
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.PRODUCT PIPELINE ANALYSIS (PHASE II & III)
TABLE 02.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 03.PIRFENIDONE MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.NINTEDANIB MARKET, BY REGION, 2020–2030($MILLION)
TABLE 05.GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 06.HOSPITAL- PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 08.IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 09.IDIOPATHIC PULMONARY FIBROSIS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 10.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 11.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 12.NORTH AMERICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 13.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 14.U.S. IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 15.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 16.CANADA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 17.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 18.MEXICO IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 19.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 20.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 21.EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 22.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 23.GERMANY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 24.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 25.FRANCE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 27.UK IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 28.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 29.ITALY IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 30.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 31.SPAIN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 32.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 33.REST OF EUROPE IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 34.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 35.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 36.ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 37.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 38.JAPAN IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 40.CHINA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 41.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 42.INDIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 43.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 44.AUSTRALIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 46.SOUTH KOREA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 47.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 48.REST OF ASIA-PACIFIC IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 49.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 50.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030($MILLION)
TABLE 51.LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 52.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 53.BRAZIL IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 54.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 55.SAUDI ARABIA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 56.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 57.SOUTH AFRICA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DRUG TYPE, 2020–2030 ($MILLION)
TABLE 59.REST OF LAMEA IDIOPATHIC PULMONARY FIBROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 60.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 61.ASTRAZENECA: OPERATING SEGMENTS
TABLE 62.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 63.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 64.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 65.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 66.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 67.BRISTOL-MYERS SQUIBB: OPERATING SEGMENTS
TABLE 68.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 69.BIOGEN: COMPANY SNAPSHOT
TABLE 70.BIOGEN: OPERATING SEGMENTS
TABLE 71.BIOGEN: PRODUCT PORTFOLIO
TABLE 72.FIBROGEN: COMPANY SNAPSHOT
TABLE 73.FIBROGEN: OPERATING SEGMENTS
TABLE 74.LILLY: PRODUCT PORTFOLIO
TABLE 75.ROCHE: COMPANY SNAPSHOT
TABLE 76.ROCHE: OPERATING SEGMENTS
TABLE 77.ROCHE: PRODUCT PORTFOLIO
TABLE 78.GNI: COMPANY SNAPSHOT
TABLE 79.GNI: PRODUCT SEGMENTS
TABLE 80.GNI: PRODUCT PORTFOLIO
TABLE 81.GALAPAGOS: COMPANY SNAPSHOT
TABLE 82.GALAPAGOS: OPERATING SEGMENTS
TABLE 83.GALAPAGOS: PRODUCT PORTFOLIO
TABLE 84.MISSION: COMPANY SNAPSHOT
TABLE 85.MISSION: OPERATING SEGMENTS
TABLE 86.MISSION: PRODUCT PORTFOLIO
TABLE 87.SHIONOGI: COMPANY SNAPSHOT
TABLE 88.SHIONOGI: OPERATING SEGMENTS
TABLE 89.SHIONOGI: PRODUCT TYPE PORTFOLIO
LIST OF FIGURES
FIGURE 01.IDIOPATHIC PULMONARY FIBROSIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2020
FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05.HIGH BARGAINING POWER OF BUYERS
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTES
FIGURE 08.MODERATR INTENSITY OF COMPETITIVE RIVALRY
FIGURE 09.IMPACT ANALYSES
FIGURE 10.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR PIRFENIDONE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 11.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR NINTEDANIB, BY COUNTRY, 2020 & 2030 (%)
FIGURE 12.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR HOSPITAL- PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF IDIOPATHIC PULMONARY FIBROSIS MARKETFOR ONLINE PROVIDER, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.ASTRAZENECA: REVENUE, 2018–2020($MILLION)
FIGURE 16.ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2020(%)
FIGURE 17.ASTRAZENECA: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 18.BOEHRINGER INGELHEIM: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 20.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 21.REVENUE, 2018–2020 ($MILLION)
FIGURE 22.BRISTOL-MYERS SQUIBB: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 23.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.BIOGEN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.FIBROGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.FIBROGEN: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 27.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.ROCHE: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 29.ROCHE: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 30.GNI: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.GALAPAGOS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.SHIONOGI: REVENUE, 2018–2020 ($MILLION)